सत्यमेव जयते

Government of India
Central Drugs Standard Control Organisation (Headquarter)
(Directorate General of Health Services)
FDA Bhavan, ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail: dci@nic.in

File No. BIO/CT/24/000159

Dated 10.06.2025

.

To,

M/s Lupin Limited,
KALPATARU INSPIRE , 3rd FLOOR , Off WESTERN EXPRESS HIGHWAY,
SANTACRUZ (EAST), MUMBAI (India) – 400055

Subject: Application for grant of permission to conduct Phase IV clinical trial entitled "A multicentre, open label, prospective, single-arm, non-comparative, non-randomized phase IV study to evaluate safety and efficacy of Injection Ranibizumab (of Sponsor Lupin Limited) given as intravitreal injection in preterm infants with Retinopathy of Prematurity" vide Protocol No. 24-VIN-0299; Version 02 dated 29 Apr 2025-regarding

Ref. No.: Your Application No. BIO/CT04/FF/2024/46558 dated 13.12.2025

Sir,

With reference to your application No.: BIO/CT04/FF/2024/46558 dated 13.12.2025, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

(I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8

(II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial.

(VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules.

(VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal.

(IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination.

(X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI.

(XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter.

(XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter.

(XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial.

(XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority.

(XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial.

(XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.06.11 10:35:51 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Licensing Authority

File. No. BIO/CT/24/000159

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s Lupin Limited, KALPATARU INSPIRE , 3rd FLOOR , Off WESTERN EXPRESS HIGHWAY, SANTACRUZ (EAST), MUMBAI (India) – 400055 to conduct Phase IV clinical trial entitled – "A multicentre, open label, prospective, single-arm, non-comparative, non-randomized phase IV study to evaluate safety and efficacy of Injection Ranibizumab (of Sponsor Lupin Limited) given as intravitreal injection in preterm infants with Retinopathy of Prematurity" vide **Protocol No. 24-VIN-0299; Version 02 dated 29 Apr 2025** in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date: 10.06.2025

RAJEEV SINGH RAGHUVANSHI
Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.06.11 10:36:34 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority

Annexure:

Details of new drug or investigational new drug:

<table>
<tr><td>Names of the new drug or investigational new drug:</td><td>Ranibizumab solution for injection 10 mg/ml (r-DNA origin)</td></tr>
<tr><td>Therapeutic class</td><td>VEGF Antagonist</td></tr>
<tr><td>Dosage form:</td><td>Solution for intravitreal injection
Strength – 10 mg/mL
Pack style - 1 vial per carton.
Route of administration - intravitreal route in the eyes</td></tr>
<tr><td>Composition:</td><td>Composition for Ranibizumab solution for injection 10 mg/ml (r-DNA origin). Each single use vial of 0.23 mL contains Ranibizumab 2.3 mg:
<table>
<tr><th>Name of Ingredients</th><th>Quantity (per mL)</th></tr>
<tr><td>Ranibizumab (r-DNA origin), in-house</td><td>10 mg</td></tr>
<tr><td>L-Histidine, Ph.Eur, BP, JP, USP</td><td>0.321 mg</td></tr>
<tr><td>L-Histidine hydrochloride monohydrate Ph.Eur, BP, JP</td><td>1.662 mg</td></tr>
<tr><td>α,α-trehalose dihydrate, Ph.Eur, BP, JP, USP-NF</td><td>100 mg</td></tr>
<tr><td>Polysorbate 20, IP, Ph. Eur., BP, USP-NF and In-House</td><td>0.1 mg</td></tr>
<tr><td>Water for Injection, In-House, USP, IP, Ph.Eur., BP, JP</td><td>q.s to 1 mL</td></tr>
</table>
One ml contains 10 mg ranibizumab. Each vial contains 2.3 mg of ranibizumab in 0.23 ml solution. This provides a usable amount to deliver a single dose of 0.05 ml containing 0.5 mg ranibizumab toadult patients.</td></tr>
<tr><td>Indications:</td><td>Indicated in preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I(stage 1+, 2+, 3 or 3+), zone II(stage 3+) or AP-ROP(aggressive posterior ROP)disease</td></tr>
</table>

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1.	Regional Institute of Ophthalmology Medical College & Hospital, Department of Clinical Research, Room no. 88, College Street, Kolkata, 700073, West Bengal, India.	INSTITUTIONAL ETHICS COMMITTEE For Human Research, Medical College ,Kolkata88, College Street Kolkata West Bengal -700073 India EC Reg. No.: ECR/287/Inst/WB/2013/RR-24	Dr Soumyadeep Majumdar
2.	Regional Institute of Ophthalmology Medical College & Hospital, Indira Gandhi Institute of Medical	Institutional Ethics Committee, IGIMS ,Sheikhpura Indira Gandhi Institute Of Medical Sciences Sheikhpura Raja Bazar Patna Bihar	Dr Abhishek Anand

	sciences Sheikh pura Patna - 800014 Bihar	800014 India EC Reg. No.: ECR/640/Inst/BR/2014/RR-20	
3.	AIIMS Raipur, Gate No 1, Great Eastern Rd, opposite Gurudwara, AIIMS Campus, Tatibandh, Raipur, Chhattisgarh 492099	INSTITUTE ETHICS COMMITTEE, AIIMS RAIPUR, Room no. 2103, 2nd Floor, South Wing, Medical College Complex, Gate No. 5, All India Institute of Medical Sciences, Tatibandh, GE Road, Raipur, 492099 EC Reg. No.: ECR/714/Inst/CT/2015/RR-21	Dr Vijaya Sahu
4.	Shanti Saroj Netralay, Department of Clinical Research,Room no. ,A.N Gaikwad, 901/902, Beside Sundar Nagar, Anand Nursing Home Road, Off Sangli-Miraj Rd, Miraj, Maharashtra, India-416410 Sangl	IEC-Saishwari Clinic -Hospital for Mental Health, Saishwari Clinic - Hospital for Mental Health Yashwant Co Op Housing Society Sangali Road,Miraj MIRAJ Sangli Maharashtra -416410 EC Reg. No.: ECR/1245/Inst/MH/2019/RR-24	Dr. Sharad Bhomaj
5.	Drashtipunj Eye Hospital PVT.LTD, Department of Clinical Research, Room no.NA, Vashikunj Complex, Saguna More, Bailey Road, Danapur, Patna, Bihar - 801503, India	INSTITUTIONAL ETHICS COMMITTEE ,BSL EyecareRoad NO 2 Rajendar Nagar Patna Bihar,India EC Reg. No. ECR/1328/Inst/BR/2019	Dr Ratnesh Ranjan
6.	North Bengal Medical College, Susrutanagar Siliguri, Darjeeling Siliguri Darjeeling West Bengal - 734012 India	INSTITUTIONAL ETHICS COMMITTEE, North Bengal Medical College, Susrutanagar Siliguri, Darjeeling Siliguri Darjeeling West Bengal -734012 India EC Reg No. ECR/1701/Inst/WB/2022	Dr. Pekila Lama Bhutia
7.	Netralayam Superspeciality Eye Care Centre and BB Eye foundation, Kolkata	BB Eye Foundation VIP Ethics Committee,BB Eye Foundation VIP(Unit of kolkata Eye care hospital Pvt.Ltd)Shree Tower, RAA –36, II, VIP Rd, Raghunathpur, Rajarhat, Kolkata, West Bengal 70005	Dr.Sudipta Das

		EC Reg No. ECR/1019/Inst/WB/2017/RR-21	
8.	Kashyap Memorial Eye Hospital Pvt. Ltd.Purulia Rd, near Dangratoli Chowk, Dangartoli, Nayatoli, Ranchi, Jharkhand 834001	Kashyap Memorial Eye Hospital Pvt. Ltd ComplexPurulia Rd, Near Dangratoli Chowk Dangratoli, Nayatoli, Ranchi, (Jharkhand) 834001, India EC Reg No. ECR/1790/Inst/JH/2023	Dr. Bibhuti Kashyap
9.	PBMAs H.V. Desai Eye Hospital, 93, Tarawade Vasti, Mohammadwadi, Hadapsarc, Pune -411060	Institutional Ethics Committee PBMAs H v Desai eye hospital, 93, Tarawade Vasti, Mohammadwadi, Hadapsar, Pune, Maharashtra -411060 EC Reg No. ECR/234/Inst/MH/2013/RR-22	Dr Sucheta Kulkarni
10.	Prayag Retina care,8/9/4 panna lal road,opp. To D.R.T office,Prayagraj-211002(UP)and Inited Institute of medical Sciences,rawatpur, Prayaragraj.	Indira IVF Hospital Ethics Committee Prayagraj Indira IVF Hospital Private Limited Civil Station, Elgin Road, Near Hanuman Mandir Civil EC Reg No. ECR/1782/INST/UP/2023	Dr. Manish Tandon
11.	Netrodaya -The Eye City,561/562 -Near Dafi Toll Plaza NH-2,Varanasi 221008,Uttar Pradesh	Netrodaya The Eye City LLP, Arazi No 651 And 652 Near Dafi Toll Plaza, Dafi Varanasi Varanasi Uttar Pradesh -221008 India EC Reg No. ECR/1832/Inst/UP/2023	Dr. Abhishek Dixit